Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells

Cytotherapy

Volumn 13, Issue 6, 2011, Pages 753-764

  Siegers, Gabrielle M ^a   Dhamko, Helena ^a   Wang, Xing Hua ^a   Mathieson, A Mark ^a   Kosaka, Yoko ^a   Felizardo, Tania C ^a   Medin, Jeffrey A ^a   Tohda, Shuji ^b   Schueler, Julia ^c,d   Fisch, Paul ^d   Keating, Armand ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c CHARLES RIVER LABORATORIES   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

B cell chronic lymphocytic leukemia; cell therapy; immunotherapy; V 1 cells; T cell

Indexed keywords

CD56 ANTIGEN; CHROMIUM 51; CONCANAVALIN A; FAS ANTIGEN; GREEN FLUORESCENT PROTEIN; HLA ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; BLOOD; CELL CLONE; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY TEST; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTOTOXICITY; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 79959272887     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.553595     Document Type: Article

References (51)

1. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67:5-8. (Pubitemid 46142752)
2. De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Roederer M. Ontogeny of gamma delta T cells in humans. J Immunol. 2004;172:1637-45. (Pubitemid 38116811)
3. Hviid L, Akanmori BD, Loizon S, Kurtzhals JA, Ricke CH, Lim A, et al. High frequency of circulating gamma delta T cells with dominance of the V(delta)1 subset in a healthy population. Int Immunol. 2000;12:797-805. (Pubitemid 30410452)
4. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975-1026.
5. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727-9.
6. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science. 1994;264: 267-70.
7. Morita CT, Lee HK, Leslie DS, Tanaka Y, Bukowski JF, Marker-Hermann E. Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells. Microbes Infect. 1999;1:175-86.
8. Burk MR, Mori L, De Libero G. Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol. 1995;25:2052-8.
9. Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175: 5471-80.
10. Bukowski JF, Morita CT, Brenner MB. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity. 1999;11:57-65. (Pubitemid 29359957)
11. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS, et al. Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med. 2000;191:937-48.
12. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14:123-33. (Pubitemid 32206515)
13. Ensslin AS, Formby B. Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst. 1991;83:1564-9.
14. Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, et al. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/ Vdelta2 T cells in tumor immunity. Eur J Immunol. 1997;27: 3368-79. (Pubitemid 28018034)
15. Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol. 2002;215:32-44.
16. Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 2001;27:1087-93. (Pubitemid 32591194)
17. Wright A, Lee JE, Link MP, Smith SD, Carroll W, Levy R, et al. Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. J Exp Med. 1989;169:1557-64. (Pubitemid 19126815)
18. + lymphokine-activated killer cells against K562 and Daudi cells. Cancer Immunol Immunother. 1993;36:331-6.
19. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384-92. (Pubitemid 30463353)
20. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol. 1995;154:3932-40.
21. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/ delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother. 2001;50:115-24. (Pubitemid 32480555)
22. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, et al. Human intestinal Vdelta1 + lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996; 183:1681-96. (Pubitemid 26134310)
23. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol. 2001;125:256-63. (Pubitemid 32722298)
24. + subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes. J Immunol. 1992;149: 3984-9.
25. Duval M, Yotnda P, Bensussan A, Oudhiri N, Guidal C, Rohrlich P, et al. Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia. Leukemia. 1995;9: 863-8.
26. Meeh PF, King M, O 'B rien RL, Muga S, Buckhalts P, Neuberg R, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006;55:1072-80.
27. Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, et al. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom. 2006;70:379-90.
28. Lamb LS Jr, Gee AP, Hazlett LJ, Musk P, Parrish RS, O ' Hanlon TP, et al. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999;1: 7-19.
29. Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, et al. Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001;27:601-6. (Pubitemid 32401457)
30. Bartkowiak J, Kulczyck-Wojdala D, Blonski JZ, Robak T. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma. 2002;49:86-90. (Pubitemid 34493666)
31. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64:9172-9. (Pubitemid 39665533)
32. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-7.
33. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114:2044-50.
34. Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008;21:375-89.
35. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010;37:1191-7.
36. Lucas C, Ingoure S, Soule E, Faria B, Audibert F, Blery M, et al. IPH1101, the first specific gamma delta T cell agonist, shows potent immuno-biological efficacy in low grade follicular lymphoma patients when combined with rituximab: results from a phase II study. Blood. 2009;114:583.
37. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, et al. Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med. 1990;171: 1567-79. (Pubitemid 20167551)
38. Amendola M, Venneri MA, BiffiA, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol. 2005;23: 108-16. (Pubitemid 41724633)
39. Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, et al. Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA. 2004;101: 16909-14. (Pubitemid 39601337)
40. Tohda S, Nara N, Murohashi I, Aoki N. Establishment of an interleukin-3-dependent leukemic cell line from a patient with chronic lymphocytic leukemia in the acute phase. Blood. 1991;78:1789-94.
41. McCoy JL, Herberman RB, Rosenberg EB, Donnelly FC, Levine PH, Alford C. 51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue- culture cells. Natl Cancer Inst Monogr. 1973;37:59-67.
42. Siegers GM, Al-Beirouti BM, Mathieson AM, Felizardo TC, Helke S, Medin JA, et al. Gamma delta T cells (GDTCs) to eliminate minimal residual disease (MRD) in chronic myeloid leukemia (CML): a pre-clinical model. Blood. 2008;112: 215-6.
43. Mistry AR, O' C allaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology. 2007;121:439-47.
44. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett. 2010;297:126-36.
45. Chang CP, Yang MC, Liu HS, Lin YS, Lei HY. Concanavalin A induces autophagy in hepatoma cells and has a therapeutic effect in a murine in situ hepatoma model. Hepatology. 2007; 45:286-96.
46. Liu Z, Li X, Ding X, Yang Y. In silico and experimental studies of concanavalin A: insights into its antiproliferative activity and apoptotic mechanism. Appl Biochem Biotechnol. 2010; 162:134-45.
47. Liu B, Li CY, Bian HJ, Min MW, Chen LF, Bao JK. Antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A on human melanoma A375 cells. Arch Biochem Biophys. 2009;482:1-6.
48. Forsdyke DR. Role of receptor aggregation in complement-dependent inhibition of lymphocytes by high concentrations of concanavalin A. Nature. 1977;267:358-60. (Pubitemid 8119788)
49. + gamma delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res. 2008;14:4232-40.
50. Norian LA, Kucaba TA, Earel JK, Knutson T, Vanoosten RL, Griffith TS. Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors. J Oncol. 2009;2009:408038.
51. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.